Doxorubicin-Loaded Platelet Decoys for Enhanced Chemoimmunotherapy Against Triple-Negative Breast Cancer in Mice Model

References

• Garrido-Castro AC, Lin NU, Polyak K. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov. 2019;9(2):176–198. doi:10.1158/2159-8290.CD-18-1177
   PubMed Web of Science ®Google Scholar
• Gazinska P, Grigoriadis A, Brown JP, et al. Comparison of basal-like triple-negative breast cancer defined by morphology, immunohistochemistry and transcriptional profiles. Mod Pathol. 2013;26(7):955–966. doi:10.1038/modpathol.2012.244
   PubMed Web of Science ®Google Scholar
• Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26(8):1275–1281. doi:10.1200/JCO.2007.14.4147
   PubMed Web of Science ®Google Scholar
• Viscardi G, Tralongo AC, Massari F, et al. Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis. Eur J Cancer. 2022;177:175–185. doi:10.1016/j.ejca.2022.09.031
   PubMed Web of Science ®Google Scholar
• Srivastava S, Mohanty A, Nam A, Singhal S, Salgia R. Chemokines and NSCLC: emerging role in prognosis, heterogeneity, and therapeutics. Semin Cancer Biol. 2022;86(Pt 2):233–246. doi:10.1016/j.semcancer.2022.06.010
   PubMedGoogle Scholar
• Flynn M, Pickering L, Larkin J, Turajlic S. Immune-checkpoint inhibitors in melanoma and kidney cancer: from sequencing to rational selection. Ther Adv Med Oncol. 2018;10:1758835918777427. doi:10.1177/1758835918777427
   Web of Science ®Google Scholar
• Schmid P, Rugo HS, Adams S, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, Phase 3 trial. Lancet Oncol. 2020;21(1):44–59. doi:10.1016/S1470-2045(19)30689-8
   PubMed Web of Science ®Google Scholar
• Adams S, Diéras V, Barrios CH, et al. Patient-reported outcomes from the Phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer. Ann Oncol. 2020;31(5):582–589. doi:10.1016/j.annonc.2020.02.003
   PubMed Web of Science ®Google Scholar
• Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 2012;12(12):860–875. doi:10.1038/nrc3380
   PubMed Web of Science ®Google Scholar
• Dosset M, Joseph ELM, Rivera Vargas T, Apetoh L. Modulation of Determinant Factors to Improve Therapeutic Combinations with Immune Checkpoint Inhibitors. Cells. 2020;9(7):1727. doi:10.3390/cells9071727
   PubMed Web of Science ®Google Scholar
• Jiang M, Zeng J, Zhao L, et al. Chemotherapeutic drug-induced immunogenic cell death for nanomedicine-based cancer chemo-immunotherapy. Nanoscale. 2021;13(41):17218–17235. doi:10.1039/d1nr05512g
   PubMed Web of Science ®Google Scholar
• Singh M, Nicol AT, DelPozzo J, et al. Demystifying the Relationship Between Metformin, AMPK, and Doxorubicin Cardiotoxicity. Front Cardiovasc Med. 2022;9:839644. doi:10.3389/fcvm.2022.839644
   PubMed Web of Science ®Google Scholar
• Bagdasaryan AA, Chubarev VN, Smolyarchuk EA, et al. Pharmacogenetics of drug metabolism: the role of gene polymorphism in the regulation of doxorubicin safety and efficacy. Cancers. 2022;14(21):5436. doi:10.3390/cancers14215436
   PubMed Web of Science ®Google Scholar
• Ke WR, Chang RYK, Chan HK. Engineering the right formulation for enhanced drug delivery. Adv Drug Deliv Rev. 2022;191:114561. doi:10.1016/j.addr.2022.114561
   PubMed Web of Science ®Google Scholar
• Kong L, Yang C, Zhang Z. Organism-generated biological vesicles in situ: an emerging drug delivery strategy. Adv Sci. 2022;e2204178. doi:10.1002/advs.202204178
   Web of Science ®Google Scholar
• Vadasz B, Chen P, Yougbaré I, et al. Platelets and platelet alloantigens: lessons from human patients and animal models of fetal and neonatal alloimmune thrombocytopenia. Genes Dis. 2015;2(2):173–185. doi:10.1016/j.gendis.2015.02.003
   PubMedGoogle Scholar
• Deng C, Zhao X, Chen Y, et al. Engineered platelet microparticle-membrane camouflaged nanoparticles for targeting the golgi apparatus of synovial fibroblasts to attenuate rheumatoid arthritis. ACS Nano. 2022;16(11):18430–18447. doi:10.1021/acsnano.2c06584
   PubMed Web of Science ®Google Scholar
• Li QR, Xu HZ, Xiao RC, et al. Platelets are highly efficient and efficacious carriers for tumor-targeted nano-drug delivery. Drug Deliv. 2022;29(1):937–949. doi:10.1080/10717544.2022.2053762
   PubMed Web of Science ®Google Scholar
• Wu YW, Huang CC, Changou CA, Lu LS, Goubran H, Burnouf T. Clinical-grade cryopreserved doxorubicin-loaded platelets: role of cancer cells and platelet extracellular vesicles activation loop. J Biomed Sci. 2020;27(1):45. doi:10.1186/s12929-020-00633-2
   PubMed Web of Science ®Google Scholar
• Pandey S, Shaikh F, Gupta A, Tripathi P, Yadav JS. A recent update: solid lipid nanoparticles for effective drug delivery. Adv Pharm Bull. 2022;12(1):17–33. doi:10.34172/apb.2022.007
   PubMed Web of Science ®Google Scholar
• Papa AL, Jiang A, Korin N, et al. Platelet decoys inhibit thrombosis and prevent metastatic tumor formation in preclinical models. Sci Transl Med. 2019;11(479):eaau5898. doi:10.1126/scitranslmed.aau5898
   PubMed Web of Science ®Google Scholar
• Hu Q, Sun W, Wang J, et al. Conjugation of haematopoietic stem cells and platelets decorated with anti-PD-1 antibodies augments anti-leukaemia efficacy. Nat Biomed Eng. 2018;2(11):831–840. doi:10.1038/s41551-018-0310-2
   PubMed Web of Science ®Google Scholar
• du Sert N P, Ahluwalia A, Alam S, et al. Reporting animal research: explanation and elaboration for the ARRIVE guidelines 2.0. PLoS Biol. 2020;18(7):e3000411. doi:10.1371/journal.pbio.3000411
   PubMed Web of Science ®Google Scholar
• Lau N, Haeberle AL, O’Keeffe BJ, et al. SopF, a phosphoinositide binding effector, promotes the stability of the nascent Salmonella-containing vacuole. PLoS Pathog. 2019;15(7):e1007959. doi:10.1371/journal.ppat.1007959
   PubMed Web of Science ®Google Scholar
• Bivard A, Lin L, Parsonsb MW. Review of stroke thrombolytics. J Stroke. 2013;15(2):90–98. doi:10.5853/jos.2013.15.2.90
   PubMed Web of Science ®Google Scholar
• Schwarz S, Gockel LM, Naggi A, et al. Glycosaminoglycans as Tools to Decipher the Platelet Tumor Cell Interaction: a Focus on P-Selectin. Molecules. 2020;25(5):1039. doi:10.3390/molecules25051039
   PubMed Web of Science ®Google Scholar
• Tesfamariam B. Involvement of platelets in tumor cell metastasis. Pharmacol Ther. 2016;157:112–119. doi:10.1016/j.pharmthera.2015.11.005
   PubMed Web of Science ®Google Scholar
• Fabricius HÅ, Starzonek S, Lange T. The role of platelet cell surface P-selectin for the direct platelet-tumor cell contact during metastasis formation in human tumors. Front Oncol. 2021;11:642761. doi:10.3389/fonc.2021.642761
   PubMed Web of Science ®Google Scholar
• Cheng Y, Wang C, Wang H, et al. Combination of an autophagy inhibitor with immunoadjuvants and an anti-PD-L1 antibody in multifunctional nanoparticles for enhanced breast cancer immunotherapy. BMC Med. 2022;20(1):411. doi:10.1186/s12916-022-02614-8
   PubMed Web of Science ®Google Scholar
• D C, Z Q, J M, et al. Tumors and their microenvironment dual-targeting chemotherapy with local immune adjuvant therapy for effective antitumor immunity against breast cancer. Adv Sci. 2019;6(6). doi:10.1002/advs.201801868
   Web of Science ®Google Scholar
• Qiu F, Becker KW, Knight FC, et al. Poly(propylacrylic acid)-peptide nanoplexes as a platform for enhancing the immunogenicity of neoantigen cancer vaccines. Biomaterials. 2018;182:82–91. doi:10.1016/j.biomaterials.2018.07.052
   PubMed Web of Science ®Google Scholar
• Shevtsov M, Sato H, Multhoff G, Shibata A. Novel approaches to improve the efficacy of immuno-radiotherapy. Front Oncol. 2019;9:156. doi:10.3389/fonc.2019.00156
   PubMed Web of Science ®Google Scholar
• Farag MR, Moselhy AAA, El-Mleeh A, et al. Quercetin alleviates the immunotoxic impact mediated by oxidative stress and inflammation induced by doxorubicin exposure in rats. Antioxidants. 2021;10(12):1906. doi:10.3390/antiox10121906
   Web of Science ®Google Scholar
• Xu XR, Zhang D, Oswald BE, et al. Platelets are versatile cells: new discoveries in hemostasis, thrombosis, immune responses, tumor metastasis and beyond. Crit Rev Clin Lab Sci. 2016;53(6):409–430. doi:10.1080/10408363.2016.1200008
   PubMed Web of Science ®Google Scholar
• Wang L, Wang X, Guo E, Mao X, Miao S. Emerging roles of platelets in cancer biology and their potential as therapeutic targets. Front Oncol. 2022;12:939089. doi:10.3389/fonc.2022.939089
   PubMed Web of Science ®Google Scholar
• Xu HZ, Li TF, Ma Y, et al. Targeted photodynamic therapy of glioblastoma mediated by platelets with photo-controlled release property. Biomaterials. 2022;290:121833. doi:10.1016/j.biomaterials.2022.121833
   PubMed Web of Science ®Google Scholar
• Koizume S, Miyagi Y. Tissue factor in cancer-associated thromboembolism: possible mechanisms and clinical applications. Br J Cancer. 2022;127(12):2099–2107. doi:10.1038/s41416-022-01968-3
   PubMed Web of Science ®Google Scholar
• Campia U, Moslehi JJ, Amiri-Kordestani L, et al. Cardio-oncology: vascular and metabolic perspectives: a scientific statement from the American heart association. Circulation. 2019;139(13):e579–e602. doi:10.1161/CIR.0000000000000641
   PubMed Web of Science ®Google Scholar
• Rao NV, Rho JG, Um W, et al. Hyaluronic Acid Nanoparticles as Nanomedicine for Treatment of Inflammatory Diseases. Pharmaceutics. 2020;12(10):931. doi:10.3390/pharmaceutics12100931
   PubMed Web of Science ®Google Scholar
• Thapa R, Wilson GD. The Importance of CD44 as a Stem Cell Biomarker and Therapeutic Target in Cancer. Stem Cells Int. 2016;2016:2087204. doi:10.1155/2016/2087204
   PubMed Web of Science ®Google Scholar
• Uslu D, Abas BI, Demirbolat GM, Cevik O. Effect of platelet exosomes loaded with doxorubicin as a targeted therapy on triple-negative breast cancer cells. Mol Divers. 2022. doi:10.1007/s11030-022-10591-6
   PubMed Web of Science ®Google Scholar
• Zhan M, Qiu J, Fan Y, et al. Phosphorous dendron micelles as a nanomedicine platform for cooperative tumor chemoimmunotherapy via synergistic modulation of immune cells. Adv Mater. 2023;35(3):e2208277. doi:10.1002/adma.202208277
   PubMed Web of Science ®Google Scholar
• Jeong SD, Jung BK, Lee D, et al. Enhanced Immunogenic Cell Death by Apoptosis/Ferroptosis Hybrid Pathway Potentiates PD-L1 Blockade Cancer Immunotherapy. ACS Biomater Sci Eng. 2022;8(12):5188–5198. doi:10.1021/acsbiomaterials.2c00950
   PubMed Web of Science ®Google Scholar
• Synergistic combination of targeted nano-nuclear-reactors and anti-PD-L1 nanobodies evokes persistent T cell immune activation for cancer immunotherapy - PubMed. Available from: https://pubmed.ncbi.nlm.nih.gov/36496381/. Accessed January 25, 2023.
   Google Scholar
• Rizzo A, Cusmai A, Massafra R, et al. Pathological complete response to neoadjuvant chemoimmunotherapy for early triple-negative breast cancer: an updated meta-analysis. Cells. 2022;11(12):1857. doi:10.3390/cells11121857
   PubMed Web of Science ®Google Scholar
• Emens LA, Cruz C, Eder JP, et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study. JAMA Oncol. 2019;5(1):74–82. doi:10.1001/jamaoncol.2018.4224
   PubMed Web of Science ®Google Scholar